




## RNA Editing for Alpha-1 Antitrypsin Deficiency

## What is RNA editing?

RNA editing is a new technology that corrects a disease-causing sequence in a person's RNA without making permanent changes to their DNA



## **RNA** editing

- An editing compound interacts with the disease-causing RNA and an enzyme that naturally exists within the body
- ► The three components form an **editing complex**
- ► The enzyme makes a specific change or **edit** to the RNA, releasing the **corrected RNA**
- ► The corrected RNA leads to the production of M-AAT protein

## RNA editing is designed to address key goals in the treatment of AATD



Reduces Z-AAT protein aggregation in liver



Releases circulating, functional M-AAT protein above expected therapeutic threshold (11  $\mu$ M)



Restores serum M-AAT protein to protect the lungs



One approach for individuals with 'Z' mutations, whether they have liver disease, lung disease, or both



Reversible, no permanent changes to DNA



AATD is an inherited genetic disorder that is commonly caused by a mutation that creates the 'Z allele' in the SERPINA1 gene, which results in the production of a protein called Z-AAT in place of the normal M-AAT protein.


M-AAT protein is predominately produced by the liver. Production of Z-AAT protein by the liver can lead to aggregation of the protein and an inflammatory response, causing progressive liver disease. It also means the liver is not secreting M-AAT into the blood. Loss of M-AAT in the bloodstream can lead to lung disease.



1) **Reduces** Z-AAT protein in the liver

2) **Releases** M-AAT in blood

3) **Restores** M-AAT in lungs





Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

For more information, please contact patientadvocacy@wavelifesci.com

